Related Experiment Video
Updated: May 4, 2026

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
Current status of Pseudomonas aeruginosa vaccine
Lessandra Michelim, Gregory Saraiva Medeiros, Alexandre P Zavascki1
1Infectious Diseases Service, University of Caxias do Sul - Hospital de Geral. 255 Prof Antonio Vignolli St, Caxias do Sul, 95070-561, Brazil. lessandra.michelim@ucs.br.
Abstract:
Pseudomonas aeruginosa is one of the major pathogens responsible for a wide variety of severe nosocomial and community acquired infections. Numerous vaccine candidates and several monoclonal antibodies have been developed over the past 40 years but only a few have reached clinical trials and none of these vaccine candidates has obtained market authorization. The understanding of P. aeruginosa pathogenesis and its virulence factors is essential in the identification of immunogens that can be used for a P. aeruginosa vaccine. This review summarizes the present status of vaccine development for this important pathogen.
Related Concept Videos
Vaccine Production
Atypical Pneumonia
Clinical Significance of Antibiotic Resistance

